Health Canada
- Status: approved
🇨🇦 Paprizumab combined with cisplatin and 5-FU in Canada
Paprizumab combined with cisplatin and 5-FU (Paprizumab combined with cisplatin and 5-FU) regulatory status in Canada.
Marketing authorisation
Paprizumab combined with cisplatin and 5-FU in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is Paprizumab combined with cisplatin and 5-FU approved in Canada?
Yes. Health Canada has authorised it.
Who is the marketing authorisation holder for Paprizumab combined with cisplatin and 5-FU in Canada?
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University is the originator. The local marketing authorisation holder may differ — check the official source linked above.